Nature Communications (Oct 2018)

Phenome-wide association studies across large population cohorts support drug target validation

  • Dorothée Diogo,
  • Chao Tian,
  • Christopher S. Franklin,
  • Mervi Alanne-Kinnunen,
  • Michael March,
  • Chris C. A. Spencer,
  • Ciara Vangjeli,
  • Michael E. Weale,
  • Hannele Mattsson,
  • Elina Kilpeläinen,
  • Patrick M. A. Sleiman,
  • Dermot F. Reilly,
  • Joshua McElwee,
  • Joseph C. Maranville,
  • Arnaub K. Chatterjee,
  • Aman Bhandari,
  • Khanh-Dung H. Nguyen,
  • Karol Estrada,
  • Mary-Pat Reeve,
  • Janna Hutz,
  • Nan Bing,
  • Sally John,
  • Daniel G. MacArthur,
  • Veikko Salomaa,
  • Samuli Ripatti,
  • Hakon Hakonarson,
  • Mark J. Daly,
  • Aarno Palotie,
  • David A. Hinds,
  • Peter Donnelly,
  • Caroline S. Fox,
  • Aaron G. Day-Williams,
  • Robert M. Plenge,
  • Heiko Runz

DOI
https://doi.org/10.1038/s41467-018-06540-3
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 13

Abstract

Read online

Testing the association between genetic variants and a range of phenotypes can assist drug development. Here, in a phenome-wide association study in up to 697,815 individuals, Diogo et al. identify genotype–phenotype associations predicting efficacy, alternative indications or adverse drug effects.